Calcium, Phosphorus and PTH in Patients with End Stage of Chronic Kidney Disease, Undergoing Hemodialysis

Serfa Faja and Amir Shoshi
Additional contact information
Serfa Faja: PhD candidate in medical sciences

European Journal of Natural Scinces and Medicine Articles, 2020, vol. 3

Abstract: Renal hyperparathyroidism (rHPT) is a common complication of chronic kidney disease characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D. Patients with rHPT experience increased rates of cardiovascular problems and bone disease. The Kidney Disease: Improving Global Outcomes guidelines recommend that screening and management of rHPT be initiated for all patients with chronic kidney disease stage 3 (estimated glomerular filtration rate, - 60 mL/min/1.73 m2). Since the 1990s, improving medical management with vitamin D analogs, phosphate binders, and calcimimetic drugs has expanded the treatment options for patients with rHPT, but some patients still require a parathyroidectomy to mitigate the sequelae of this challenging disease.

Keywords: Calcium; Phosphorus and PTH in Patients with End Stage of Chronic Kidney Disease; Undergoing Hemodialysis (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://brucol.be/index.php/ejmn/article/view/5031 (text/html)
https://brucol.be/files/articles/ejmn_v3_i2_20/Faja.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eur:ejmnjr:24

DOI: 10.26417/214rmd38q

Access Statistics for this article

More articles in European Journal of Natural Scinces and Medicine Articles from Revistia Research and Publishing
Bibliographic data for series maintained by Revistia Research and Publishing ().